PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
A phase 3 trial testing PM8002 in triple-negative breast cancer, active and no longer recruiting.
Overview
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC is a phase 3 interventional study registered as NCT06419621, led by Biotheus, and active but no longer recruiting when checked on 2026-09-11. Official title: A Multicenter, Randomised, Double-blind Phase III Study of PM8002 or Placebo in Combination With Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer(TNBC). Planned enrolment is 392 participants (estimated). The study started in 2024-06-11 and primary completion is expected in 2027-07. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
- TrialA Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Shares BioNTech and the tag ctgov-ingest.
- TrialA Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Shares BioNTech and the tag ctgov-ingest.
- TrialA Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialA Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialFDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TrialA Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Shares Triple-negative breast cancer (TNBC) and the tag ctgov-ingest.
- TreatmentBNT113
Shares BioNTech and the tag ctgov-ingest.